Subgrouping rarer cancers and clinical trial design
Role of BRAF mutation in the treatment for melanoma
What's the best option in the treatment of melanoma?
OS rates and prognostic categories for BRAF-mutated melanoma when treated with combination therapy
The involvement of patients in regulatory discussions and measuring the needs of patients